jedi_delta,,2019-05-20 13:40:00,19.692,EXEL This companys trajectory is similar to INCY One major blockbuster molecule for multiple disease indications For 2019 INCYs Ruxo will generate 165B in Revs Inclusig another 100M EXELs Cabo will generate close to 1B Lots of CASH 1B for EXEL and 17B for INCY Deep trials for multiple indications Both are boltons for larger Pharma One for Oncologic and the other for Hematologic indications
s0r0s,True,2019-05-20 11:46:00,19.619,EXEL pretty impressed with this today
jeffg3412,True,2019-05-20 10:55:00,19.401,EXEL STNE BLIN AMD very low risk entry here imo loading up for a swing
EstimizeAlerts,,2019-05-20 10:06:00,19.075,Heres what 7 Estimize analysts believe EXEL will report for Q2 2019 EPS Reporting 0731 AMCestimizecomintroexelcha
marketchameleonwins,,2019-05-20 09:32:00,19.25,EXEL 21Jun19 Straddle Implies a 102 move May 21 UBS Global Healthcare Conference marketchameleoncomOvervie
